Pneumocystis jirovecii Antibody (SPM365): sc-65527

Pneumocystis jirovecii (SPM365) is a IgM kappa light chain antibody that detects Pneumocystis jirovecii. Anti-Pneumocystis jirovecii antibody (SPM365) is available as a non-conjugated format. Pneumocystis is a genus of fungi which can be pathogenic in mammals. Pneumocystis jirovecii (previously designated Pneumocystis carinii in humans) is a microscopic fungus that exists in the lungs of many humans. This fungus is normally benign, but can cause Pneumocystis carinii pneumonia (PCP) in immunocompromised individuals. During PCP, Pneumocystis deteriorates the basement membrane of the lung, causing a rise in LDH levels and compromising gas exchange. Oxygen is less able to diffuse into the blood, leading to hypoxia, which, along with high arterial CO2 levels, stimulates ventilation, thereby causing dyspnea. Pneumocystis can also invade other visceral organs, such as the liver, spleen and kidney. Symptoms of Pneumocystis infection include shortness of breath, non-productive cough, low grade fever, weight loss and night sweats. PCP can be fatal if not treated aggressively.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Pneumocystis jirovecii Antibody (SPM365) References:

1. [Dyspnea, fever in immunodeficiency. Pneumocystis carinii pneumonia].  |  Schwietert, M. 1999. Praxis (Bern 1994). 88: 340-1. PMID: 10097644
2. Pneumocystis carinii carriage in immunocompromised patients with and without human immunodeficiency virus infection.  |  Takahashi, T., et al. 2002. J Med Microbiol. 51: 611-692. PMID: 12132780
3. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients.  |  Roblot, F., et al. 2002. Eur J Clin Microbiol Infect Dis. 21: 523-31. PMID: 12172743
4. A new name (Pneumocystis jiroveci) for Pneumocystis from humans.  |  Stringer, JR., et al. 2002. Emerg Infect Dis. 8: 891-6. PMID: 12194762
5. Widespread visceral calcifications in disseminated Pneumocystis carinii infection: CT characteristics.  |  Feuerstein, IM., et al. 1990. J Comput Assist Tomogr. 14: 149-51. PMID: 2298984
6. Pneumocystis carinii: oxygen uptake, antioxidant enzymes, and susceptibility to oxygen-mediated damage.  |  Pesanti, EL. 1984. Infect Immun. 44: 7-11. PMID: 6323317
7. Search for extrapulmonary Pneumocystis carinii in an animal model.  |  Oz, HS., et al. 1996. J Parasitol. 82: 357-9. PMID: 8604119
8. [Pneumocystis carinii and aspergillus pneumonia in immunosuppression in rapidly progressing glomerulonephritis of the anti-glomerular basement membrane type].  |  Späth, M. and Schollmeyer, P. 1996. Med Klin (Munich). 91: 603-6. PMID: 8984320
9. Diagnostic strategies for Pneumocystis carinii pneumonia.  |  Kroe, DM., et al. 1997. Semin Respir Infect. 12: 70-8. PMID: 9195672

The preferred Pneumocystis jirovecii antibody is Pneumocystis jirovecii Antibody (3F6): sc-57980.